Filing identity and reporting period
The supplied filing is Quintiles Transnational Holdings Inc.’s Form 10-K for the fiscal year ended December 31, 2013, filed February 13, 2014. It is not filed under the name IQVIA Holdings Inc.; the request metadata and filing registrant do not match. The filing reports full-year results and unaudited quarterly data, including Q4 2013.
Financial performance
| Metric | FY 2013 | FY 2012 | Change |
|---|---|---|---|
| Service revenue | $3.808 billion | $3.692 billion | +3.1% reported; +5.1% constant currency |
| Total revenue, including reimbursed expenses | $5.100 billion | $4.866 billion | +4.8% |
| Operating income | $462.3 million | $396.4 million | +16.6% |
| Operating margin on service revenue | 12.1% | 10.7% | Improved |
| Net income attributable to shareholders | $226.6 million | $177.5 million | +27.6% |
| Diluted EPS | $1.77 | $1.51 | +17.2% |
| Cash from operating activities | $397.4 million | $335.7 million | +$61.7 million |
| Capital expenditures | $92.3 million | $71.3 million | Increased |
Q4 2013 service revenue was $1.004 billion, operating income $127.0 million, and net income attributable to shareholders $73.0 million. In Q4 2012, the corresponding figures were $945.8 million, $94.4 million, and $35.0 million.
- Segments: Product Development revenue rose 7.0% to $2.920 billion, with operating income up 17.7% to $562.3 million and segment margin of 19.3% versus 17.5%. Integrated Healthcare Services revenue fell 7.8% to $888.6 million; operating income declined 30.4% to $42.1 million and margin was 4.7% versus 6.3%.
- Cash and liquidity: Year-end cash and equivalents were $778.1 million, including $320.1 million in the United States. The company reported a $300 million undrawn revolving facility and said available cash, operating cash flow and revolver access should fund operations and debt obligations for at least 12 months.
- Debt and balance sheet: Debt and capital leases were approximately $2.061 billion, down from $2.445 billion. Total liabilities were $3.734 billion, total assets $3.067 billion, and shareholders’ deficit $667.5 million. The December refinancing replaced prior term loans with a $2.061 billion Term Loan B-3 due in 2018, at 3.75% at year-end; $945 million of variable-rate debt was hedged.
- Commercial indicators: Net new business increased 9% to $4.899 billion; backlog increased 13% to $9.855 billion. The company cautions that cancellations, delays, changing scope and project duration make backlog an imperfect indicator of future revenue.
Material changes and unusual items
- Reported service revenue growth was restrained by approximately $70.6 million of adverse foreign-exchange impact. Product Development grew, while Integrated Healthcare Services declined in constant currency as prior-period scope reductions and cancellations were not yet offset by new work.
- The company acquired Novella Clinical in September 2013 for approximately $146.6 million net of acquired cash, with potential earn-outs up to $21 million. The acquisition added oncology, medical-device and emerging-company capabilities.
- The May 2013 IPO generated approximately $489.6 million of net proceeds. Proceeds were used mainly to repay debt, terminate the sponsor management agreement, and fund the Novella acquisition. The company also paid a $25 million management-agreement termination fee and recorded $19.8 million of debt-extinguishment losses.
- FY 2013 included $14.1 million of restructuring expense. A February 2014 plan, subsequent to year-end, authorized up to $13 million of additional restructuring costs and approximately 400 position reductions.
- Operating cash flow improved, but receivables and unbilled services increased, and management cited a five-day increase in DSO and longer customer payment terms as a cash-flow headwind. No shareholder dividends were paid in 2013; the company said it did not expect regular dividends in the foreseeable future.
Outlook, commentary and risks
Management estimated that outsourced clinical-development services would grow 6%–8% annually from 2013 through 2016, supported by R&D spending and increased outsourcing. This is an industry outlook, not company-specific financial guidance. The filing provides no clear numerical company revenue or earnings forecast.
- Key risks include customers’ ability to terminate or delay contracts, project cancellations and cost overruns, and the uncertain timing of backlog conversion.
- Other material exposures include substantial leverage and variable interest rates, foreign-currency movements, data privacy and cybersecurity, regulatory compliance, clinical-trial liability, competition, and acquisition integration.
- The company reported compliance with debt covenants and stated that legal proceedings were not expected to have a material adverse effect. Its independent auditor issued an unqualified opinion on the consolidated financial statements.
- Foreign earnings: most undistributed earnings were designated indefinitely reinvested abroad; repatriating approximately $368.8 million of those earnings was estimated to create about $32 million of additional tax liability.
Important facts for investors to verify
- Confirm the intended issuer: this filing is for Quintiles Transnational Holdings Inc., not IQVIA Holdings Inc.
- Review whether Product Development growth and margin gains can continue, and whether Integrated Healthcare Services stabilizes after its revenue and profit declines.
- Assess backlog quality, cancellation terms, expected conversion timing, DSO and collection trends.
- Check debt repayment capacity, covenant headroom, refinancing terms and exposure to unhedged rate changes.
- Evaluate the effects of the Novella acquisition, restructuring actions, IPO-related costs and foreign-currency movements on recurring results and cash generation.